A one year study evaluating anticoagulant drugs as an adjunct in the management of congestive heart failure has been carried out on 300 patients. Depo-Heparin and dieumarol were the drugs employed. The effect of anticoagulant therapy upon the incidence of thromboembolic comp)lications and mortality has been studied.
T HE PURPOSE of this paper is to evaluate the influence of anticoagulant therapy on the incidence of thromboembolic complications and mortality in patients with congestive heart failure. The fact that patients with congestive heart failure are prone to develop thromboembolic complications is well known. Kinsey and White' found pulmonary infarction to be present in 24 of 50 autopsied cases of congestive heart failure. In 1947, Carlotti, Hardy, Linton and White2 noted that of 273 patients with pulmonary infarcts, the admitting diagnosis was congestive heart failure in 104.
In 1948, Anderson and Hull reported the use of dicumarol in 61 of 142 patients with congestive heart failure. Thromboembolic complications occurred in 15 per cent of the untreated group and in only 8 per cent of the patients treated with dicumarol. In 1948, Wishart and Chapman14 described the action of dicumarol therapy in 61 patients with congestive heart failure. A comparable control group was not observed. The mortality in this series was 32.8 per cent and the incidence of thromboembolic phenomena during therapy was 6.5 per cent. During the course of the work one of us (D. C. L.) was a Trainee, National Heart Institute, Bethesda, Md. This study was aided by grants from the Los Angeles Heart Association and the Upjohn Company, Kalamazoo, Mich.
The Depo-Heparin used in this study was generously supplied by the Upjohn Company, Kalamazoo, Mich.
The expected incidence of thromboembolic phenomena w-as reported to be 22 per centt.
Early in 1950, Harvey and Finch5 reported a study of dicumarol therapy in 80 of 180 patients with congestive heart failure; 100 similar patients did not receive anticoagulant treatment. Fatal thromboembolic complications, proved by autopsy. were found in 9 of the 100 control patients and in noise of the dicumaroltreated group. The mortality was 17 per cent in the control group and only 9 per cent in the group receiving dicumarol. Recently, Anderson and Hull,6 in a progress report, described 297 patients with congestive heart failure, of whom 147 received dicumarol. The mortality was 13.3 per cent in the control group, and 7.5 per cent in the group treated with dicumarol.
METHOD OF STUDY During a 12 month period (July 1949 to July 1950) a study was made of the action of anticoagulant therapy in 300 patients with congestive heart failure. Shortly after admission to the medical wards of the Los Angeles County Hospital, all patients with congestive heart failure were seen by one of the authors. Initially, it was established that the patient had frank congestive heart failure. Only patients with both right and left heart failure (cardiac enlargement, basal rales, elevated venous pressure, hepatomegaly, and edema) were included. Patients with only left heart failure, acute or recent mvocardial infarction, renal disease, diabetes and other major complicating illnesses were excluded.
Patients qualifying for the study were alternately placed in one of three groups. Patients in the first group were used as a control series and did not receive anticoagulant therapy. Patients in the second group received dicumarol and those in the third group, Depo-Heparin. This procedure was adhered to as rigiclly as possible. The work-up an(l routine therapy of these patients was managed by the medical residents and house staff. The dosage and duration of anticoagulant therapy was determined by the authors. Control prothrombin and coagulation times were performed within 24 hours after hospital admission. Daily prothrombin determinations were made according to the method of Quick. Coagulation times were determined by a four tube technic, following the Lee-Wahite method. Anticoagulant therapy was started within 24 hours after hospital admission. It was continued until congestive heart failure was no longer present, the patient was ambulant, and soon to be discharged.
Dicumarol was administered in a dosage calculated to keep the prothrombin time between 10 and 30 per cent. Depo-Heparin sodium without vasoconstrictors was given in a dosage calculated to keep the coagulation time between 30 and 60 minutes. It w-as found that 200 mg. of this type of Depo-Heparin given every 20 hours resulted in the most satisfactory prolongation of the coagulation time. This dosage was adjusted for those patients who were excessively over-or underweight. In all three groups the largest number of patients were inl the seventh decade, followed by the sixth, eighth and fifth decades. In respect to age distribution, the groups appear comparable.
Sex and Race. The distribution between the two sexes, and between the white and Negro races was compiled and found to be similar in the three groups.
Type of Heart Disease. Hypertensive, arteriosclerotic and rheumatic heart disease were almost the only etiologic types of heart disease present in our series of patients. The distribution of patients with these three respective types of heart disease among the three groups, while not equal, is comparable and adequate. (See table 2.) RESULTS Thromboembolic Complications. In the control group of 100 patients, proved pulmonary infarction was present in 8. Three of these survived, all of whom had definite clinical and roentgenologic findings of pulmonary infarction. These 3 patients received dicumarol promptly and recurrences wsere not observed.
In 5 of the 8 patients, the pulmonary infarc- with rheumatic heart disease had fatal outcomes which were considered to be the result of cerebral emboli. Permissions for iiecropsy in these patients w-ere not obtained.
Ini the group treated with dicumarol, 2 patients developed thromboembolic complications; one, a nonfatal pulmonary infarct and the other, a fatal cerebral embolus. Of the 7 patients in this group who died, autopsies were obtained in 2. One had rheumatic heart disease, and a cerebral embolus was found at autopsy. The other had hypertensive heart disease, and congestive heart failure was the only finding at autopsy. Age distribution and mortality were correlated, and it wsas found that the greatest reduction in mortality was in the seventh decade where 10 deaths occurred in the untreated group. Among patients in the same decade who were treated with dicumarol and DepoHeparin, there wvere one and two deaths respectively. However, the number of patients in the seventh decade in the two groups which received anticoagulant therapy wN-as less than the number in the control group wshich received this therapy.
An attempt to correlate type of heart disease and mortality showed that the greatest number of deaths in the control group occurred in patients wvith rheumatic heart disease. An incidence of nine deaths among patients waith rheumatic disease in the control group Avas reduced to one and 2 deaths respectively in the groups treated with dicumarol and Depo-Heparin.
Complications of Anticoagulant Therapy. There wNere 4 instances of bleeding among the 100 patients treated with dicumarol; epistaxis in 2, hematuria in one and melena ill one. In all of these, temporary interruption of therapy resulted in a correction of the complication.
Hemorrhagic complications wN-ere found in 5 of the group receiving Depo-Heparin. There were 2 instances of ecchymoses, one of hematoma at the site of injection, one of epistaxis. In 2 of these patients the Depo-Heparin was given at 12 hour intervals instead of 20 hour intervals as ordered. The fifth patient, previously referred to, developed a fatal cerebral hemorrhage. The coagulation time in this patient Aw-as 36 minutes shortly before death; at autopsy no other evidence of hemorrhage wvas present. SUMMARY 1. Three hundred patients have been studied;
